The Development of New MI Probes

The OICR has focused significant resources on issues relating to breast, prostate and pancreatic cancer; three diseases that would benefit greatly with access to better MI probes. Two areas are the focus of the CPDC discovery team: New MI probes for breast cancer detection and stratification, and pancreatic cancer imaging. Specifically, the CPDC aims to develop and translate the next generation of agents targeting neuropeptide Y, which is highly overexpressed on breast tumours, and CXCR4, which is a protein that is widely expressed on a number of tumours including pancreatic cancer. The latter class of agents will be designed to have the dual purpose of imaging pancreatic tumours and for guiding surgical resection. For each target, the goal is to identify each lead agent, evaluate them in phase I trials and select the most promising candidate(s) for a phase II trial. The “stretch goal” will be to have sufficient preliminary data and to have identified additional funding to support a phase II trial in year 4.